Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound amino acid glucose is a nutraceutical formulation primarily investigated for its role in managing osteoarthritis. It is believed to contain glucosamine, an amino sugar, and potentially other amino acids. Glucosamine acts as a precursor for glycosaminoglycans and proteoglycans, which are vital components of joint cartilage. Its proposed mechanism involves stimulating cartilage synthesis, inhibiting cartilage degradation, and exhibiting anti-inflammatory properties, thereby aiming to alleviate pain and improve joint function in individuals with osteoarthritis. The product is being clinically investigated by The Third Hospital of Peking University and BY-HEALTH Co., Ltd.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound amino acid glucose.